Fornovo San Giovanni (Bidachem)
Founded in 1981, Fornovo San Giovanni serves both – Human Pharma and Animal Health
Search
Dortmund
The site in Dortmund plays a key role in manufacturing the propellant-free inhaler RESPIMAT® as well as all other products within the RESPIMAT
3 Ways Boehringer Ingelheim's Corporate Values Align with Hispanic Heritage
3 Ways Boehringer Ingelheim's Corporate Values Align with Hispanic Heritage
Kobe
The Kobe Pharma Research Institute takes part in the global research and development activities for human pharmaceuticals.
Giving Back to Those Who Serve Our Country
Giving Back to Those Who Serve Our Country
Sant Cugat del Vallès (Barcelona)
Boehringer Ingelheim settled in Spain in 1952. For almost 70 years, t
Ingelheim
The company headquarters of Boehringer Ingelheim are located in Ingelheim, Germany.
Life Forward
In everything we do we can shape and influence the future for the better: Learn more about “Life forward” and how our innovations improve lives.
Boehringer Ingelheim and Junior Achievement: A decade of inspiring futures
Boehringer Ingelheim celebrates its decade-long partnership and volunteering milestone.
Lyon
The Lyon region is a key global hub for the Animal Health business of the company, encompassing research, development, production and supply of veterinary products.
Sunshine Act Compliance
Sunshine Act Compliance
Boehringer Ingelheim Vetmedica, Inc. to Establish North America and U.S. Headquarters in Duluth, Ga. Following Close of BI/Sanofi Asset Swap
Boehringer Ingelheim Vetmedica, Inc. to Establish North America and U.S. Headquarters in Duluth, Ga. Following Close of BI/Sanofi Asset Swap
Hurricane help: Our unwavering support of storm victims
Ensuring access to healthcare, meals, and medication for people and animals across the southeast.
Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration
Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration
First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for TRADJENTA® (linagliptin) Tablets in Type 2 Diabetes
First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for TRADJENTA® (linagliptin) Tablets in Type 2 Diabetes
FDA Grants Priority Review to Boehringer Ingelheim’s Biologics License Application for Idarucizumab*
FDA Grants Priority Review to Boehringer Ingelheim’s Biologics License Application for Idarucizumab*
New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline
New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline
Investigational Compound Granted FDA Orphan Drug Designation
U.S. FDA Grants Orphan Drug Designation to Investigational Compound for Idiopathic Pulmonary Fibrosis
BI & Lilly Announce Outcome of FDA Advisory Meeting | Boehringer Ingelheim US
The EASE phase III program includes two Phase III clinical trials to investigate the efficacy, safety and tolerability of once-daily Empagliflozin.
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer’s trials
Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer’s trials
FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children
FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children
FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease
FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease
Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control
Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control
U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes
U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes